Monday March 19, 2018
Home Politics Modi in China...

Modi in China: Prime Minister likely to sign $10-billion deals



By NewsGram Staff Writer

​Prime Minister Narendra Modi is planning to seal deals worth $10 billion on the first day of his trip to China, according to the reports by a leading English daily of the country on Thursday.

Talking about his plans during the China visit, the Global Times said, “Both the countries are likely to sign deals worth $10 billion during Modi’s first visit as prime minister. The visit will also include going to Beijing and Shanghai as he attempts to attract investments for Indian manufacturing and infrastructure.”

Modi arrived at Xian,capital of China’s Shaanxi province, today. This is the first leg of his three-nation tour, which will also include Mongolia and South Korea.

He is scheduled to meet Chinese President Xi Jinping on Thursday in Xian.

“It is a rare practice for a Chinese leader to receive a foreign leader outside the capital city Beijing,” told Jiang Jingkui, director of the Department of South Asian Languages at Peking University to the Global Times.

“It has been less than a year since Xi’s maiden visit to India in September, when he went to Modi’s hometown (Ahmedabad) in Gujarat. This makes Xi’s invitation to Modi to visit Xian a reciprocal gesture of goodwill,” Jingkui added.

The differences between both the countries can be overcome by the increasing economic exchanges which have drawn the two emerging Asian economies closer than ever, the report examines.

India has also signed up as a founding member of the China-initiated Asian Infrastructure Investment Bank.

Indian and China are the biggest trading partner with bilateral trade of $70 billion and India’s trade deficit with China rose to $37.8 billion last year.

According to the report, Modi is expected to bridge this gap during his three-day China visit by tapping into the potential of the Chinese market.​

Click here for reuse options!
Copyright 2015 NewsGram

Next Story

Pentavalent vaccine: Doctors raise red flag

In spite of the data presented in this paper from a large cohort, the authors point out that the evidence is merely circumstantial and not conclusive

the new Hepatitis B vaccine for adults is called Heplisav-B.
India's PV to be reexamined because of its harmful effects. .
  • Pentavalent vaccine was introduced in India six years ago
  • It is since then have been a cause of many deaths
  • Doctors want it to be reexamined before continuing its use

Pentavalent vaccine (PV), that was introduced by India a little over six years ago, doubled the deaths of children soon after vaccination compared to the DPT (Diphtheria-Pertussis-Tetanus) vaccine, according to a new study that calls for a “rigorous review of the deaths following vaccination with PV”.

Health officials have launched a campaign targeting nearly 24 million people with a one-fifth dose of the vaccine. Wikimedia Commons
PV has been cause of many deaths in past years. Wikimedia Commons

Government records show that there were 10,612 deaths following vaccination (both PV and DPT) in the last 10 years. There was a huge increase in these numbers in 2017, which the Health Ministry has promised to study. “The present analysis could be a starting point in the quest to reduce the numbers of such deaths,” authors of the new study say.

The study by Dr Jacob Puliyel, Head of Pediatrics at St Stephens Hospital, and Dr V. Sreenivas, Professor of Biostatistics at the All-India Institute of Medical Sciences (AIIMS), both in New Delhi, is published in the peer-reviewed Medical Journal of Dr D.Y. Patil University.

PV is a combination of the DPT vaccine and two more vaccines against Haemophilus influenza type B (Hib) and hepatitis B. Starting December 2011, PV was introduced into India’s immunisation programme to replace DPT vaccine in a staged manner with a view to adding protection against Hib and Hepatitis B without increasing the number of injections given to infants.

Doctors have raised concerns over these vaccines. Wikimedia Commons
Doctors have raised concerns over these vaccines. Wikimedia Commons

But sporadic reports of unexplained deaths following immunisation with PV had been a matter of concern. Puliyel, Sreenivas and their colleagues undertook the study to find out if these deaths were merely coincidental or vaccine-induced.

The authors obtained data of all deaths reported from April 2012 to May 2016 under the Right to Information Act. Data on deaths within 72 hours of administering DPT and PV from different states were used.

For their study, the authors assumed that all deaths within 72 hours of receiving DPT are natural deaths. Using this figure as the baseline, they presumed that any increase in the number of deaths above this baseline among children receiving PV must be caused by this vaccine.

Also Read: With Medicine Running Out, Venezuelans With Transplant Live in Fear

According to their analysis of the data provided by the government, there were 237 deaths within 72 hours of administering the Pentavalent vaccine — twice the death rate among infants who received DPT vaccine.

Extrapolating the data, the authors have estimated that vaccination of 26 million children each year in India would result in 122 additional deaths within 72 hours, due to the switch from DPT to PV.

“There is likely to be 7,020 to 8,190 deaths from PV each year if data from states with the better reporting, namely Manipur and Chandigarh, are projected nationwide,” their report says.

It is important to make sure that these vaccines are reexamined peroperly. VOA

The authors note that while the study looks at the short-term increase in deaths (within three days of vaccination) it does not calculate the potential benefits of PV on infant mortality, for example by protection against lethal diseases like Haemophilus influenza.

In spite of the data presented in this paper from a large cohort, the authors point out that the evidence is merely circumstantial and not conclusive. “These findings of differential death rates between DPT and PV do call for further rigorous prospective population-based investigations,” the study concludes. IANS